title: Quantifying Trace Amounts of Aggregates in Biopharmaceuticals Using Analytical Ultracentrifugation Sedimentation Velocity: Bayesian Analyses and F Statistics.
abstract: Analytical ultracentrifugation-sedimentation velocity (AUC-SV) is often used to quantify high molar mass species (HMMS) present in biopharmaceuticals. Although these species are often present in trace quantities, they have received significant attention due to their potential immunogenicity. Commonly, AUC-SV data is analyzed as a diffusion-corrected, sedimentation coefficient distribution, or c(s), using SEDFIT to numerically solve Lamm-type equations. SEDFIT also utilizes maximum entropy or Tikhonov-Phillips regularization to further allow the user to determine relevant sample information, including the number of species present, their sedimentation coefficients, and their relative abundance. However, this methodology has several, often unstated, limitations, which may impact the final analysis of protein therapeutics. These include regularization-specific effects, artificial "ripple peaks," and spurious shifts in the sedimentation coefficients. In this investigation, we experimentally verified that an explicit Bayesian approach, as implemented in SEDFIT, can largely correct for these effects. Clear guidelines on how to implement this technique and interpret the resulting data, especially for samples containing micro-heterogeneity (e.g., differential glycosylation), are also provided. In addition, we demonstrated how the Bayesian approach can be combined with F statistics to draw more accurate conclusions and rigorously exclude artifactual peaks. Numerous examples with an antibody and an antibody-drug conjugate were used to illustrate the strengths and drawbacks of each technique.
authors.affiliation: Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., 1 Burtt Rd, Andover, Massachusetts, USA. Lucas.Wafer@Pfizer.com.
authors.forename: Lucas
authors.initials: L
authors.lastname: Wafer
authors.affiliation: Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., 1 Burtt Rd, Andover, Massachusetts, USA.
authors.forename: Marek
authors.initials: M
authors.lastname: Kloczewiak
authors.affiliation: Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., 1 Burtt Rd, Andover, Massachusetts, USA.
authors.forename: Yin
authors.initials: Y
authors.lastname: Luo
mesh_terms: D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000032:analysis; D001499:Bayes Theorem; D001688:Biological Products / Q000032:analysis*; D003627:Data Interpretation, Statistical; D004340:Drug Contamination; D014461:Ultracentrifugation / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products
keywords: SEDFIT; analytical ultracentrifugation; bayesian analysis; monoclonal antibody; sedimentation velocity